Navigation Links
Fuel from market waste
Date:2/9/2012

r and fed to the microorganisms," explains Schliemann. It is vital that a correct balance be maintained in the plant at all times, because the various microorganisms require constant environmental conditions to do their job.

Another advantage of the new plant lies in the fact that absolutely everything it generates can be utilized; the biogas, the liquid filtrate, and even the sludgy residue that cannot be broken down any further. A second sub-project in Reutlingen comes into its own here, involving the cultivation of algae. When the algae in question are provided with an adequate culture medium, as well as carbon dioxide and sunlight, they produce oil in their cells that can be used to power diesel engines. The filtrate water from the biogas plant in Stuttgart contains sufficient nitrogen and phosphorus to be used as a culture medium for these algae, and the reactor facility also provides the researchers with the carbon dioxide that the algae need in order to grow; while the desired methane makes up around two thirds of the biogas produced there, some 30 percent of it is carbon dioxide. With these products put to good use, all that is left of the original market waste is the sludgy fermentation residue, which is itself converted into methane by colleagues at the Paul Scherrer Institute in Switzerland and at the Karlsruhe Institute of Technology.

Others involved in this network project, which goes by the name of ETAMAX, include energy company EnBW Energie Baden-Wrttemberg and Daimler AG. The former uses membranes to process the biogas generated in the market-place plant, while the latter supplies a number of experimental vehicles designed to run on natural gas. The five-year project is funded to the tune of six million euros by the German Federal Ministry of Education and Research (BMBF). If all the different components mesh together as intended, it is possible that similar plants could in future spring up wherever large quantities of organic waste
'/>"/>

Contact: Ursula Schliessmann
ursula.schliessmann@igb.fraunhofer.de
49-711-970-4222
Fraunhofer-Gesellschaft
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. MSU technology spin-out company to market portable biohazard detection
2. Biometrics Market in India 2010 - 2014
3. EB Selected by Raptor ID To Develop the RaptorPAD and RaptorONE -- High-Tech Biometric Devices for Government Markets
4. Nanotechnology in Medical Applications: The Global Market
5. Cell Therapeutics, Inc. Expects That the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) May Issue an Opinion on the Marketing Authorization Application ("MAA") on Pixuvriâ„¢ in Mid-February
6. AppTech Launches Cutting-Edge Age Recognition App for Mobile Marketing
7. Biotech start-up brings DNA-sequencing to the medical market
8. Veritec and National Identity Solutions (NIS) Sign Significant License Agreement Entering Into a $500 Billion Marketplace
9. High toxic levels found at school, market neighboring informal e-waste salvage site in Africa
10. From lab to marketplace
11. Angel investor market stabilizes in first half of 2011, UNH Center for Venture Research finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Fuel from market waste
(Date:5/14/2015)... May 14, 2015 Research and Markets ... "Fingerprint Sensors Market in Smart Mobile Devices " ... believes that 2014 was a watershed year for fingerprint ... of ,Apple Pay,. Apple gave fingerprint sensors a raison ... service. Fingerprint sensors are a must-have feature in flagship ...
(Date:5/11/2015)... Calif. , May 11, 2015  Synaptics ... of human interface solutions, today announced the appointment ... President and Chief Financial Officer, reporting to ... replaces Synaptics, current Chief Financial Officer, Kathleen ... 2014. Mr. Ali brings extensive ...
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... of an unknown perpetrator who has committed a crime will ... MC scientists, in collaboration with their Polish colleagues, have discovered ... color. Their findings will be published today in the Springer ... that on the basis of DNA information it is possible ...
... (PHILADELPHIA) An international team of researchers led ... Penn Medicine,s Institute for Translational Medicine and Therapeutics, ... Paris-based Fondation Leducq to study the molecular genetics ... Mechanisms of Novel Genes Associated with Plasma Lipids ...
... Many young people who,ve just learned that they have cancer ... lives could rob them of their ability ever to have ... population: Of the 1.5 million people diagnosed with cancer in ... The good news, according to an article in ...
Cached Biology News:Hair color of unknown offenders is no longer a secret 2Penn Medicine researcher receives $6 million grant for cardiovascular disease study 2Advancements in fertility preservation provide oncology patients new options 2Advancements in fertility preservation provide oncology patients new options 3
(Date:6/1/2015)... June 1, 2015  Fennec Pharmaceuticals, Inc. (TSX: ... interim results from a poster presented today entitled, ... randomised phase III trial of the efficacy of ... receiving cisplatin (Cis) monotherapy for standard risk hepatoblastoma ... Society of Clinical Oncology (ASCO) 2015 Annual Meeting ...
(Date:6/1/2015)... , ROCHESTER, Minn. and ... 2015 Baxter Ventures, the venture arm of ... Clinic and Velocity Pharmaceutical Development, LLC ("VPD") today announced ... a unique collaboration model initiated by Baxter Ventures to ... in the areas of immunology, hematology, and oncology. Following ...
(Date:6/1/2015)... Esperance Pharmaceuticals Inc. today reported positive results ... in ovarian cancer patients resistant to paclitaxel. EP-100 is ... cancer cells that overexpress luteinizing hormone-releasing hormone (LHRH) receptors ... wide range of cancers. Results of ... were presented at the 2015 ASCO Annual Meeting ...
(Date:6/1/2015)... 2015 Research and Markets ( ... the "2015 Strategies in European Immunoprotein ... offering. This new 273-page report ... market, including emerging tests, technologies, instrumentation, sales ... leading suppliers. Companies Mentioned: ...
Breaking Biology Technology:Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 2Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 5Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 3
... - CEO Michael V. Novinski to Discuss Plans ... CEDAR KNOLLS, N.J., Jan. 31 Emisphere,Technologies, Inc. ... will host a,teleconference on Thursday, February 7, at ... V. Novinski will discuss the company,s,emerging business strategy. ...
... Names Board of Directors, SAN DIEGO, Jan. ... developing therapeutics for the,treatment of Alzheimer,s disease, announced ... Series A round of financing. The financing was ... Alta Partners. Additional,investors included AgeChem Venture Fund, and ...
... Foundation Continues Research Initiatives in Search of a Cure and Therapies ... ... N.J., Jan. 31 The Christopher and Dana,Reeve Foundation (CDRF), which ... improving the quality of life for people,living with paralysis through grants, ...
Cached Biology Technology:Emisphere to Host Business Strategy Conference Call on February 7 2Emisphere to Host Business Strategy Conference Call on February 7 3Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimer's Treatments 2Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimer's Treatments 3Christopher and Dana Reeve Foundation Awards Nearly $2 Million in Individual Research Grants 2Christopher and Dana Reeve Foundation Awards Nearly $2 Million in Individual Research Grants 3
... Science LAS-3000 imaging system combines new ... user interface, providing significantly improved system ... modularities. The system is especially dedicated ... standard system for Western blotting applications.,Fuiji's ...
This pump accomodates StemSep ; pump feed columns of the following sizes : 0.3in., 0.5in., 0.6in., and 1.0in.....
... m7G Capping system features the ... of the components needed to ... the end of di- or ... feature high efficiency capping (virtually ...
... Removal , , Removes ... cross-reactivity with other proteins , Simple, just ... Economical new surface technology, not based on ... with protein analysis. SurfactAway offers a simple ...
Biology Products: